It’s not just genomic scientists that are dealing with enormous amounts of DNA sequence data – the clinician will soon be next. However, the explosion in linking disease with genetics, and the realization that the FDA will require gene testing prior to the prescription of potentially hundreds of drugs, will challenge the storage capacity required for clinical data. In addition, recent studies have shown the utility of whole genome analysis (6 billion bases of DNA per individual), discovering a cause of Charcot–Marie–Tooth disease, one of the most commonly inherited neurological disorders, which affects approximately 1 in 2500 people. In addition, other disease-causing genes have also recently been found by looking in families that inherit a variety of different types of mutations.
This is no longer the “spit-test” parties and subsequent Single Nucleotide Polymorphism (“SNiP”) analysis that Direct-to-Consumer companies offer to consumers, often only showing modest increased risk for disease prediction (typically ranging from 1.3 – 1.8 fold greater than another individual). Also, as reported here by me in a previous blog, the mutations that lead to Adverse Drug Events often convey a 100 – 10000+ fold greater risk for that patient.
“There will be an explosion of family sequencing that will identify disease genes,” Dr. Leroy Hood, Director of the Institute for Systems Biology, said in a recent interview. “My prediction is that most of us will have our genome sequences done, included as part of our medical records, and it will be an important part of predictive medicine.” This suggests that “all Healthcare IT systems will soon be overwhelmed by patient genomic and pharmacogenomic data.”
As stated by Dr. George Church, Professor of Genetics at Harvard Medical School and Director of the Center for Computational Genetics, said in a Newsweek interview, – The message is not “Here’s your destiny. Get used to it!” Instead, it’s “Here’s your destiny, and you can do something about it!” Diseases result from a combination of genetic vulnerability and lifestyle. If you know you have high risk of certain diseases, it’s in your interest to know and practice the lifestyle that reduces your risk—and the younger, the better.”
Whole genome sequence analysis, while still expensive, is dropping in price in a dramatic fashion (See Figure below), much faster than the proverbial Moore’s law. The latest research findings have started a “tsunami” in looking at the entire genome in patients with both Mendelein traits and those with common, complex diseases. This has created a need for more computing resources. For example, Washington University’s current scientific and clinical genomic data center, a 16,000-square-foot facility that houses approximately 5,000 processors and more than 5 petabytes of disk storage, is nearly 90 percent full. The University just received a $14M grant from the National Institutes of Health to increase storage capacity.
One obvious solution may be Cloud Computing storage or offsite server farms, connected to the EHR through Web Services by a Secure Socket Layer (SSL), that helps protect patient confidentiality. However, this approach has not fully reached the mainstream of development in the EHR realm.
Adapted from presentation from Dr. George Church at the Cold Spring Harbor Lab, “Personal Genomes” meeting: